Breaking News
Investing Pro 0
🚨 NDVA surged 43%. This AI Chipmaker Could Be Next See Analysis
Close

MannKind Corp (MNKD)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow MannKind's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
4.320 0.000    0.00%
06/06 - Closed. Currency in USD ( Disclaimer )
Pre Market
4.320
-0.000
-0.000%
13:00:00 - Real-time Data
  • Volume: 2,271,279
  • Bid/Ask: 4.280 / 4.500
  • Day's Range: 4.260 - 4.440
Type:  Equity
Market:  United States
MannKind 4.320 0.000 0.00%

MNKD News

 
This page features the latest MannKind share news. Assess the latest information about the MannKind stock.
MannKind Appoints Burkhard Blank as Chief Medical Officer
MannKind Appoints Burkhard Blank as Chief Medical Officer By Investing.com - May 24, 2023

MannKind (NASDAQ:MNKD) Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung...

MannKind earnings beat by $0.01, revenue topped estimates
MannKind earnings beat by $0.01, revenue topped estimates By Investing.com - May 09, 2023

Investing.com - MannKind (NASDAQ: MNKD) reported first quarter EPS of $-0.040, $0.01 better than the analyst estimate of $-0.050. Revenue for the quarter came in at $40.62M versus the consensus...

MannKind Appoints Lauren M. Sabella as COO
MannKind Appoints Lauren M. Sabella as COO By Investing.com - Mar 27, 2023

On March 21, 2023, Lauren M. Sabella was appointed by the board of directors of MannKind (NASDAQ:MNKD) as Executive Vice President, Chief Operating Officer of the Company, with such appointment to be...

MannKind Misses Q4 EPS by 2c
MannKind Misses Q4 EPS by 2c By Investing.com - Feb 23, 2023

MannKind (NASDAQ:MNKD) reported Q4 EPS of ($0.07), $0.02 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $36.06 million versus the consensus estimate of $35.22 million.

MannKind Earnings, Revenue beat in Q3
MannKind Earnings, Revenue beat in Q3 By Investing.com - Nov 08, 2022

Investing.com - MannKind reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations. MannKind announced earnings per share of $-0.060 on revenue of...

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

MNKD Comments

Write your thoughts about MannKind Corp
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Ooi Chinsoon
Ooi Chinsoon Nov 14, 2020 5:17
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Diabetes inhaler...great potential stocks
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email